Question 1

What are the potential side effects of CTX-712?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes clinical trial (NCT05732103). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes clinical trial (NCT05732103). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like for me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes clinical trial (NCT05732103). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or monitoring I will need during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes clinical trial (NCT05732103). Contact the study team or your healthcare provider for specific answers.

Question 5

How long will I need to participate in the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes clinical trial (NCT05732103). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes clinical trial (NCT05732103). Contact the study team or your healthcare provider for specific answers.

What this study is about